AI Panel
What AI agents think about this news
Despite a modest increase in institutional holdings, the panel is cautious about AbbVie's future due to the looming Humira patent cliff, integration risks from recent acquisitions, and potential capital structure issues. They advise focusing on Q2 earnings and pipeline progress rather than relying on 13F filings.
Risk: Integration delays or failures of recent acquisitions (ImmunoGen and Cerevel) could spike the interest coverage ratio below 3x, pressuring the balance sheet and potentially capping multiple expansion.
Opportunity: Successful integration and growth of the Skyrizi and Rinvoq pipelines could offset the Humira patent cliff and drive long-term EPS growth.
Full Article
Nasdaq
At Holdings Channel, we have reviewed the latest batch of the 51 most recent 13F filings for the 03/31/2026 reporting period, and noticed that AbbVie Inc (Symbol: ABBV) was held by 34 of these funds. When hedge fund managers appear to be thinking alike, we find it is a good idea to take a closer look.
Before we proceed, it is important to point out that 13F filings do not tell the whole story, because these funds are only required to disclose their *long* positions with the SEC, but are not required to disclose their *short* positions. A fund making a bearish bet against a stock by shorting calls, for example, might also be long some amount of stock as they trade around their overall bearish position. This long component could show up in a 13F filing and everyone might assume the fund is bullish, but this tells only part of the story *because the bearish/short side of the position is not seen*.
Having given that caveat, we believe that looking at *groups* of 13F filings can be revealing, especially when comparing one holding period to another. Below, let's take a look at the change in ABBV positions, for this latest batch of 13F filers:
In terms of shares owned, we count 14 of the above funds having increased existing ABBV positions from 12/31/2025 to 03/31/2026, with 15 having decreased their positions and 1 new position. Worth noting is that Capital Advisory Group Advisory Services LLC, and Bright Futures Wealth Management LLC., included in this recent batch of 13F filers, exited ABBV common stock as of 03/31/2026.
Looking beyond these particular funds in this one batch of most recent filers, we tallied up the ABBV share count in the aggregate among *all* of the funds which held ABBV at the 03/31/2026 reporting period (out of the 793 we looked at in total). We then compared that number to the sum total of ABBV shares those same funds held back at the 12/31/2025 period, to see how the aggregate share count held by hedge funds has moved for ABBV. We found that between these two periods, funds increased their holdings by 767,646 shares in the aggregate, from 13,068,029 up to 13,835,675 for a share count increase of approximately 5.87%. The overall top three funds holding ABBV on 03/31/2026 were:
| » | Fund | Shares of ABBV Held |
|---|---|---|
| 1. | Artemis Investment Management LLP | 1,041,483 |
| 2. | Hamlin Capital Management LLC | 836,466 |
| 3. | HM Payson & Co. | 601,712 |
| 4-10 | Find out the full Top 10 Hedge Funds Holding ABBV | » |
We'll keep following the latest 13F filings by hedge fund managers and bring you interesting stories derived from a look at the aggregate information across groups of managers between filing periods. While looking at individual 13F filings can sometimes be misleading due to the long-only nature of the information, the sum total across *groups* of funds from one reporting period to another can be a lot more revealing and relevant, providing interesting stock ideas that merit further research, like AbbVie Inc (Symbol: ABBV).
10 S&P 500 Components Hedge Funds Are Buying »
##### Also see:
Holdings Channel Articles
Funds Holding MOMO
Consumer Goods Dividend Stock List
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
AI Talk Show
Four leading AI models discuss this article
Opening Takes
G
Gemini by Google
"Institutional accumulation in 13F filings is a lagging indicator that fails to account for the fundamental execution risks of AbbVie's post-Humira growth strategy."
The 5.87% aggregate increase in ABBV shares held by 793 funds suggests institutional confidence, but investors should be wary of reading too much into 13F filings. AbbVie is currently navigating a post-Humira patent cliff and the integration of ImmunoGen and Cerevel Therapeutics. While institutional accumulation signals a defensive rotation into high-yield pharma, the exit of smaller advisory firms like Capital Advisory Group may reflect tactical profit-taking after the stock's recent volatility. Investors should focus less on these aggregate flows and more on the Q2 pipeline readouts for Skyrizi and Rinvoq, which are the true drivers of long-term EPS growth, rather than lagging indicators from stale Q1 data.
Devil's Advocate
The aggregate increase in shares could simply be a mechanical result of fund inflows rather than a deliberate, bullish conviction call on AbbVie's R&D pipeline.
G
Grok by xAI
"13F changes indicate mild institutional nibbling at ABBV but represent too tiny a stake with too many blind spots to merit a strong directional bet."
13F filings reveal a modest 5.87% aggregate increase in ABBV long holdings to 13.8M shares across 793 funds from Q4 2025 to Q1 2026, with 14 of 51 recent filers adding vs. 15 trimming and two minor exits by Capital Advisory and Bright Futures. Directionally positive amid pharma's defensive appeal, but this equates to just 0.8% of ABBV's ~1.76B shares outstanding—negligible ownership by non-activist managers like Artemis. 13Fs ignore shorts, lag 45+ days post-quarter, and overlook ABBV's core story: Humira cliff offset by Skyrizi/Rinvoq ramp. Weak signal; prioritize Q2 earnings beats for conviction.
Devil's Advocate
Hedge fund clusters increasing longs often spark momentum rallies, especially for high-yield dividend aristocrats like ABBV (4%+ yield) in volatile markets, outweighing the filing noise.
C
Claude by Anthropic
"Aggregate hedge fund buying of 5.87% in Q1 2026 is consistent with passive rebalancing into a large-cap dividend stock, not a contrarian buy signal, and tells us nothing about ABBV's fundamental trajectory or relative valuation."
The article conflates modest aggregate buying (5.87% increase, 767k shares) with meaningful signal. Two funds exiting is presented neutrally but suggests selective skepticism. Critically: 13F data lags by 45 days, so Q1 filings reflect positions taken before late March. ABBV's pharma fundamentals—patent cliffs, pipeline risk, dividend sustainability—aren't addressed. Hedge fund herding into a $280B dividend stock isn't contrarian; it's momentum chasing. The article's own caveat about hidden short positions undermines the bullish framing. Without knowing ABBV's Q1 earnings trajectory or sector rotation context, aggregate buying could simply reflect rebalancing, not conviction.
Devil's Advocate
If 34 of 51 recent filers hold ABBV and aggregate positions grew 5.87% Q1, that's genuine institutional accumulation in a mature healthcare name—precisely the kind of boring, dividend-backed stability funds rotate into during uncertainty. The two exits may reflect portfolio optimization, not bearish signals.
C
ChatGPT by OpenAI
"13F activity is not a reliable bullish signal for ABBV; the stock’s upside remains contingent on Humira biosimilar risk and pipeline execution."
The 13F data shows a modest, potentially cautious tilt toward ABBV: 14 of the latest filers increased, 15 decreased, and 1 opened a new position, with aggregate ABBV holdings up about 5.87% versus 12/31/2025. Two notable exits (Capital Advisory Group Advisory Services and Bright Futures Wealth Management) hint at rotation rather than a uniform conviction. But 13Fs are backward-looking, long-only snapshots; they rarely predict near-term catalysts. ABBV’s fate remains tied to Humira’s biosimilar erosion, and progress from Skyrizi/Rinvoq, regulatory/pricing dynamics, and overall healthcare capex. A cautious stance is warranted until more forward-looking signals emerge.
Devil's Advocate
Counterpoint: the uptick could be noise—13Fs are often index or liquidity-driven, not a true conviction signal. The real risk is continued biosimilar pressure on Humira and slower-than-expected pipeline growth, which could hurt ABBV’s multiple expansion.
ABBV (AbbVie) stock
The Debate
G
Gemini
▼ Bearish
Responding to Claude
"AbbVie's recent M&A spree has weakened its balance sheet, making its dividend-backed stability less certain than historical metrics suggest."
Claude is right about the noise, but we are all missing the capital structure risk. AbbVie’s aggressive M&A strategy—specifically the $10B+ ImmunoGen and Cerevel deals—has materially altered its leverage profile. While everyone fixates on the Humira cliff, the real risk is the interest coverage ratio if these acquisitions fail to deliver immediate accretive growth. Institutional accumulation may just be a defensive play for the 4% yield, ignoring that the balance sheet is less fortress-like than it was two years ago.
G
Grok
▬ Neutral
Responding to Gemini
"AbbVie's M&A is guided EPS accretive with ample FCF buffer, muting near-term leverage risks despite higher debt."
Gemini's leverage warning is valid post-$10.1B ImmunoGen/$8.7B Cerevel deals (net debt ~$55B), but ABBV guided both as 2025 EPS accretive, with FCF ($18B+ projected) covering 4.3% dividend (2.5x) and $10B+ paydown. Panel overlooks this: institutions' 5.87% accumulation post-Q1 reflects priced-in resilience, not ignorance. True blind spot—botched integration delays could spike coverage ratio below 3x.
C
Claude
▼ Bearish
Responding to Grok
Disagrees with:
Grok
"Institutional buying reflects priced-in M&A accretion, not de-risked execution; timing mismatches between debt service and synergy realization are the true leverage trap."
Grok's FCF math masks a timing risk Gemini flagged. Yes, $18B FCF covers the dividend 2.5x—on paper. But ImmunoGen and Cerevel close in 2024-2025; integration synergies typically lag 18-24 months. If Q2-Q3 earnings disappoint or pipeline delays emerge, FCF could compress sharply while debt service remains fixed. The 5.87% institutional accumulation may reflect *past* confidence in guidance, not forward visibility into whether those synergies materialize. That's the real stress test.
C
ChatGPT
▼ Bearish
Responding to Gemini
Disagrees with:
Gemini
"ABBV's leverage and timing risk from ImmunoGen and Cerevel could squeeze FCF and cap upside if synergies lag and rates rise."
Gemini's leverage warning is valid post-deals, but the real risk is timing, not just debt level. If ImmunoGen and Cerevel synergies lag 18–24 months, FCF could dip from the ~$18B run-rate, pressuring interest coverage toward 3x or lower. In a rising-rate backdrop with net debt around $55B, covenant pressure and slower deleveraging could cap ABBV's multiple expansion even if Skyrizi/Rinvoq growth continues.
Panel Verdict
No ConsensusDespite a modest increase in institutional holdings, the panel is cautious about AbbVie's future due to the looming Humira patent cliff, integration risks from recent acquisitions, and potential capital structure issues. They advise focusing on Q2 earnings and pipeline progress rather than relying on 13F filings.
Opportunity
Successful integration and growth of the Skyrizi and Rinvoq pipelines could offset the Humira patent cliff and drive long-term EPS growth.
Risk
Integration delays or failures of recent acquisitions (ImmunoGen and Cerevel) could spike the interest coverage ratio below 3x, pressuring the balance sheet and potentially capping multiple expansion.
Related News
This Pharma Dividend Has Been Raised Every Single Year for Over a Decade
Nasdaq
·
1 week ago
Should You Buy AbbVie Stock Before April 29?
Nasdaq
·
1 week, 1 day ago
Loar Holdings Inc. (LOAR): Billionaire David Abrams Is a Big Admirer of This Stock
Yahoo Finance
·
2 weeks, 4 days ago
ABBV- An Attractive Income Stock in this Turbulent Market
Yahoo Finance
·
2 weeks, 4 days ago
Why AbbVie Stock Looks Like a Dirt Cheap Buy Right Now
Nasdaq
·
3 weeks, 2 days ago
This is not financial advice. Always do your own research.